期刊
JOURNAL OF IMMUNOLOGY
卷 200, 期 8, 页码 2757-2766出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1602090
关键词
-
类别
资金
- National Institutes of Health [P01-GM095467, K08-HL130540, 2T32HL007633-31, F32 AI134019-01]
- Canadian Institute of Health Research postdoctoral fellowship
Specialized proresolving mediators (SPMs) decrease NF-kappa B activity to prevent excessive tissue damage and promote the resolution of acute inflammation. Mechanisms for NF-kappa B regulation by SPMs remain to be determined. In this study, after LPS challenge, the SPMs 15-epi-lipoxin A(4) (15-epi-LXA(4)), resolvin D1 resolvin D2, resolvin D3, and 17-epi-resolvin D1were produced in vivo in murine lungs. In LPS-activated human bronchial epithelial cells, select SPMs increased expression of the NF-kappa B regulators A20 and single Ig IL-1R related molecule (SIGIRR). Of interest, 15-epi-LXA(4) induced A20 and SIGIRR in an lipoxin A(4) receptor/formyl peptide receptor 2 (ALX/FPR2) receptor dependent manner in epithelial cells and in murine pneumonia. This SPM regulated NF-kappa B induced cytokines to decrease pathogen-mediated inflammation. In addition to dampening lung inflammation, surprisingly, 15-epi-LXA(4) also enhanced pathogen clearance with increased antimicrobial peptide expression. Taken together, to our knowledge these results are the first to identify endogenous agonists for A20 and SIGIRR expression to regulate NF-kappa B activity and to establish mechanisms for NF-kappa B regulation by SPMs for pneumonia resolution.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据